Evome Medical Technologies Inc.
LNDZF
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -17.11% | 16.82% | 48.45% | 50.09% | 58.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.11% | 16.82% | 48.45% | 50.09% | 58.00% |
| Cost of Revenue | -16.10% | 12.92% | 42.01% | 40.33% | 53.53% |
| Gross Profit | -19.02% | 24.99% | 62.13% | 71.30% | 67.18% |
| SG&A Expenses | -21.15% | 15.20% | 64.88% | 66.90% | 99.92% |
| Depreciation & Amortization | -5.72% | 22.09% | 67.57% | 102.04% | 137.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.21% | 14.26% | 50.85% | 51.74% | 71.30% |
| Operating Income | 18.05% | 5.57% | -75.70% | -73.30% | -536.11% |
| Income Before Tax | -182.89% | 10.65% | 25.49% | 34.13% | 49.90% |
| Income Tax Expenses | 100.59% | 100.85% | 100.58% | 101.52% | -1,435.76% |
| Earnings from Continuing Operations | -389.35% | -7.27% | 12.43% | 21.25% | 70.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -389.35% | -7.27% | 12.43% | 21.25% | 70.61% |
| EBIT | 18.05% | 5.57% | -75.70% | -73.30% | -536.11% |
| EBITDA | 18.34% | 24.42% | -98.85% | -78.15% | -1,648.01% |
| EPS Basic | -226.32% | 24.95% | 38.73% | 42.88% | 71.60% |
| Normalized Basic EPS | 81.98% | 85.43% | 79.77% | 85.40% | -153.01% |
| EPS Diluted | -226.32% | 25.17% | 38.89% | 43.04% | 75.64% |
| Normalized Diluted EPS | 81.98% | 85.43% | 79.77% | 85.40% | -153.01% |
| Average Basic Shares Outstanding | 29.30% | 36.17% | 35.23% | 32.05% | 32.88% |
| Average Diluted Shares Outstanding | 29.30% | 36.17% | 35.23% | 32.05% | 32.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |